With its highly potent MAO-A inhibition and extraordinary selectivity for human MAO-A over MAO-B, 1 is worth optimizing further as a new-drug lead and merits advancement to preclinical evaluations regarding utility for the treatment of neurological and psychiatric disorders. This evidence concerns the gene MAOB and psychiatric disorder.